Home|New Products||||||Technical support|

Histone 3.3 G34V - HS-388 011

A driver mutation in paediatric glioblastoma
Monoclonal mouse purified IgG
Cat. No.: HS-388 011
Amount: 100 µg
Price: 415.00 €
Cat. No. HS-388 011 100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use.
Applications WB: not recommended
IHC-P/FFPE: 1 : 1000 up to 1 : 2000 gallery  
Clone 329E5
Subtype IgG2b
Immunogen Synthetic peptide corresponding to AA 29 to 38 from human H3F3A G34V (UniProt Id: P84243)
Epitop Epitop: AA 29 to 38 from human H3F3A G34V (UniProt Id: P84243)
Reactivity Reacts with: human (P84243).
Other species not tested yet.
Specificity Specific for the H3.3 G34V mutant. Negligible cross-reactivity to H3.3 G34R, and no cross-reactivity to unmutated H3.3. K.O.
Data sheet hs-388_011.pdf
Cat. No.: HS-388 011
Quantity: 100 µg
Price: 415.00 €

H3.3 G34V mutation detection in xenograft model of pedriatic high-grade glioma

Background
The gene mutations H3.3 G34V and H3.3 G34R of histone 3.3 (H3.3 or H3F3A) have been recently identified as driver mutations in paediatric glioblastoma. G34V/R mutations are restricted to tumors of the cerebral hemispheres and are most prevalent in adolescents and young adults. These mutations cause profound upregulation of MYCN, a potent oncogene. Emerging evidence strongly suggests that paediatric glioblastomas with H3F3A mutations can be subclassified into distinct entities.

This antibody is part of the HistoSure® product line, specifically developed and tested for human pathology.